Investors

RSS Content

Codexis Named Finalist for CPhI Pharma Award for Best Innovation in Process Development

REDWOOD CITY, Calif., Oct 02, 2013 (BUSINESS WIRE) --Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced that it has been named as a finalist for the CPhI Pharma Awards in the “Best Innovation in Process Development” category. The award ceremony will take place on October 22, 2013 in Frankfurt, Germany as part of the annual CPhI Worldwide exhibition, which is expected to attract around 30,000 visitors from the pharmaceutical industry.

Codexis has been selected as a finalist following its development of the first industrially-viable biocatalysts for sulfide oxidation and Baeyer-Villiger type monooxygenations (BVMO enzymes). These optimized enzymes can be used for improved methods to manufacture chiral sulfoxides, which are important molecules for the pharmaceutical industry. Codexis has used these new enzymes to develop innovative biocatalytic processes for the production of esomeprazole and armodafinil that overcome the shortcomings of traditional manufacturing, including the ability to provide consistently high enantiometric purity and minimal sulfone impurity. The enzyme and API manufacturing processes are currently being scaled up for commercial supply.

“We are very pleased to be named a finalist for the CPhI 2013 Pharma Awards,” said John Nicols, President and CEO of Codexis. “Biocatalysis can offer faster, more efficient, cost-effective and greener manufacturing routes for many pharmaceutical products and we look forward to presenting our sulfide oxidation and BVMO enzyme technologies to the final judging panel at CPhI in Frankfurt during this well-respected industry event.”

Codexis’ BVMO enzymes are now commercially available as a screening kit that process chemists can use to explore new biocatalytic oxidation processes, which can then be readily scaled up as needed.

Codexis will be exhibiting in Hall 3.1, Booth A53 at the CPhI Worldwide exhibition.

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical production. Codexis’ proven technology enables scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development – from research to manufacturing. For more information, see www.codexis.com.

SOURCE: Codexis, Inc.

Codexis, Inc.
Investors
Paul Cox, 212-362-1200
ir@codexis.com
or
Media
Jemma Connor, +44 161 359 3255
jemma.connor@notchcommunications.co.uk

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS |

Share Page

X
| E-mail Alerts E-mail Alerts | IR Contacts Contacts | Financial Tear Sheet Tear Sheet

WE ARE BIOCATALYSISTM

We are an industrial biotechnology company delivering real business results through biobased innovation in chemicals, fuels, pharmaceuticals, consumer, and industrial products.

PHARMACEUTICAL ENZYMES


Supporting faster, cleaner, more efficient pharmaceutical manufacturing processes

Codexis delivers a range of chemicals at kilogram to multi-ton scale, through a partnered manufacturing network

CODEXIS

WHAT WE DO


Codexis delivers revolutionary biocatalytic routes that no one else can


CODEXIS

MEDIA CENTER


Visit our Media Center for the latest product information, videos, imagery, technical papers and press information.


CAREERS AT CODEXIS

An opportunity to make a difference.

Continued success at Codexis depends on the innovation, collaboration and commitment of people who are passionate about what they do


CODEXIS

INVESTOR CENTER


Access to Codexis information
for the investment community

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue